Celtaxsys

Halsa Pharmaceuticals is a biotechnology company developing therapeutics for the treatment of obesity, diabetes, cachexia and other metabolic diseases.

Bolder BioTechnology, Inc. uses advanced protein engineering technologies to create human protein pharmaceuticals with enhanced therapeutic properties. Most protein pharmaceuticals are rapidly eliminated by the body, which limits their effectiveness and requires that they be administered by frequent, often daily, injection. The company's products are designed to last longer in the body, which aims to allow them to be administered less frequently, e.g., once per week to once per month, and maximizes their therapeutic benefits to patients. Company scientists combine protein structure/function information with targeted protein modification technologies to rationally design long-acting protein pharmaceuticals that, in many cases, are 10-100-fold more potent than competing products prepared using non-targeted protein modification technologies. Bolder BioTechnology has a robust pipeline of products in preclinical development, including products for the treatment of hematological and endocrine disorders, cancer and infectious disease. The company intend to commercialize these products independently and through strategic alliances with corporate partners.

REGiMMUNE is a biotechnology company focused on the discovery, development and commercialization of immune regulatory therapeutics to treat conditions such as allergies, autoimmune diseases and inflammatory disorders.

LeukoSight Inc. is an early stage biotechnology company developing a line of therapeutics that can be used to treat autoimmune and inflammatory diseases.

XOMA (NASDAQ: XOMA) is a biotechnology company focused on the discovery and development of monoclonal antibody-based therapeutics. The Company is a late-stage biotechnology company with a diverse portfolio of innovative therapeutic antibodies. XOMA's product candidates are the result of developing monoclonal antibodies, which have created new opportunities to potentially treat a wide range of endocrine diseases.

Kylin Therapeutics, a biotechnology company, employs a RNA nanoparticle technology platform called"pRNA" to exploit the potential of RNA interference (RNAi) for treatment of many common diseases including cancer.